

Pharmacy and Therapeutics Committee Meeting

DRAFT AGENDA

600 East Broad Street – 7th Floor Conference Rooms

Richmond, Virginia 23219

Thursday, October 22, 2009 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Patrick Finnerty, DMAS Director

Call to Order

Randy Axelrod, M.D., Chairman

Approval of Minutes From April 20, 2009 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

- **Potential New Therapeutic Class Review (PDL Category)**
 - ◆ Self-Injectable Epinephrine (*Asthma / Allergy*)
 - ◆ Low Molecular Weight Heparins (*Cardiac Medication*)
 - ◆ Ulcerative Colitis – oral/rectal (*Gastrointestinal*)
 - ◆ Alpha Blockers For BPH (*Genitourinary*)
 - ◆ Androgen Hormone Inhibitors (*Genitourinary*)
 - ◆ Bile Acid Sequestrants (*Lipotropic*)
 - ◆ Hematopoietic Agents (*Miscellaneous*)
 - ◆ Progestins for Cachexia (*Miscellaneous*)

- **PDL Phase II – New Drug Review (Therapeutic Class)**
 - ◆ Benzaclin® CareKit (Acne Agent)
 - ◆ Acuvail™ (Ophthalmic Anti-inflammatory)
 - ◆ Besivance™ (Ophthalmic Antibiotic)
 - ◆ Onglyza™ (Oral Hypoglycemics – DPP-IV Inhibitor)
 - ◆ Cetraxal® (Otic Quinolones)
 - ◆ Cimzia® (Self Administered Drugs for RA)
 - ◆ Simponi™ (Self Administered Drugs for RA)
 - ◆ Nuvigil™ (Stimulants/ADHD Medications)

- **PDL Phase I – Annual Review**
 - ◆ **Antivirals**
 - Hepatitis C
 - ◆ **Asthma –Allergy**
 - Antihistamines – 2nd generation (includes combination products)
 - Beta Adrenergics – (includes short acting, long acting, nebulized and combinations)
 - COPD Anticholinergics
 - Inhaled Corticosteroids
 - Nasal Steroids
 - ◆ **Cardiac Medications**
 - Angiotensin-Converting Enzyme Inhibitors (includes combination products)
 - Angiotensin II Receptor Blockers (includes combination products, as well as renin inhibitors)
 - Beta blockers
 - Calcium Channel Blockers (includes dihydropyridine & non-dihydropyridine agents)
 - PDE-5 inhibitors (for pulmonary hypertension diagnosis)
 - Lipotropics (includes Statins, Fibric Acid derivatives, Omega 3 agents, Niacin derivatives, Niacin/Statin combinations and CAI agents)

- **PDL Phase I – Annual Review (continued)**
 - ◆ *Central Nervous System*
 - Sedative Hypnotics
 - Other Sedative Hypnotics
 - ◆ *Gastrointestinal*
 - Histamine-2 Receptor Antagonists (H-2RA)
 - Proton Pump Inhibitors
 - ◆ *Genitourinary*
 - Urinary Antispasmodics
 - ◆ *Miscellaneous*
 - Electrolyte Depleters
 - Growth Hormone
 - Topical Immunomodulators

Confidential Meeting

- **Pricing Information Discussion**

P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8

Criteria Discussion of Potentially New Classes**

P&T Committee Members

Criteria Discussion of Phase II New Drugs**

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes**

P&T Committee Members

Next Meeting – TBD

Randy Axelrod, M.D., Chairman

***Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes subject to PDL Phase I annual review, potential new drug classes, and specific new drugs in PDL Phase II classes listed on the Agenda. **All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Review – October 2008 to present
- New Drugs in PDL Phase II Drug Classes – April 2007 to present
- Potential New Drug Classes – October 2007 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmass.virginia.gov by close of business **Thursday, October 1, 2009.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by close of business **Thursday, October 1, 2009.**